Index

A
Acetaminophen, 195
N-Acetyltransferase, 104
American Society of Clinical Oncology (ASCO), 8, 191
Americans with Disabilities Act (ADA), 79, 87–88
Amsterdam Criteria, 18, 46, 171
Androgen receptor and androgen action, 210–211
Angiogenesis, 111, 117–118
APC gene, 134–135
Apoptosis, 110–111
Ashkenazi Jewish descent, 15, 39
Aspirin, 195
Ataxia telangiectasia, 103–104
 genetic testing for, 5
Autonomy
 in genetic testing, 66–74
 respect for, principle of, 62
Autosomal dominance, 206–207

B
Bayesian analysis, 42
Beckwith-Wiedemann syndrome, 214
Beneficence, principle of, 61–62
Bethesda Guidelines, 18, 46, 171
Birt-Hogg-Dube syndrome, 220
Bladder cancer
 clinical implications, 225
 epidemiology, 222–224
 incidence, 222
 potential alleles, 224–225
 specific alleles, 225
Bodian model, 7
BRCA mutation risk models, 45
BRCAPRO family history model, 7
Breast Cancer Detection Demonstration Project (BCDDP), 42
Breast cancer genetics, 91–118
Breast cancer incidence rates, age-specific, 92
Breast cancer prevention, biomarkers for, 114–116
Breast cancer research, goal of, 91
Breast cancer risk
 according to Claus model, 44
 according to Gail model, 42, 45
 assessment, 93–98
 hereditary, identifying, 104–109
 models, 42–45
Breast cancer susceptibility genes, 98–102
 low-penetrance, 104
Breast/ovarian cancer syndrome, hereditary, 4–15
 case presentations, 55–56
 genetic testing for, 5
C
Cancer
 assessing genetic risk of, 1–23
 breast. See Breast cancer
 colorectal. See Colorectal cancer
familial medullary thyroid, 245–246
hereditary breast/ovarian syndrome. See Breast/ovarian cancer syndrome, hereditary ovarian. See Ovarian cancer
prostate. See Prostate cancer
renal pelvis. See Renal pelvis cancer
site-specific, family history of, 1
sporadic, 4
testicular. See Testicular cancer
ureteral. See Ureteral cancer
Cancer and Steroid Hormone (CASH) Study, 42
Cancer biomarkers, 109–114
CancerGene software program, 7–8
Cancer information, family history of. See Family history of cancer
Cancer syndromes
 hereditary. See Inherited cancer syndromes
inherited. See Inherited cancer syndromes
Carcinoma
 cervical, 198–199
endometrial, 198
hereditary papillary renal cell (HPRC), 219–220
250  Index

Carcinoma  (continued)
renal cell.  See Renal cell carcinoma
transitional cell carcinoma-associated syndromes, 224
Cervical carcinoma, 198–199
Cervix, minimal deviation adenocarcinoma (MDC) of, 198–199
Chromosome 12, 229
Claus model, 7, 42, 95–96
breast cancer risk according to, 44
Client-centered model, 32–33
CM101, 118
Colorectal cancer, 166
genetic risk for, assessing, 15–18
hereditary nonpolyposis.  See Hereditary nonpolyposis colorectal cancer
Confidentiality of medical information, 69–70
Consent, informed, 49–50
Counseling genetic.  See Genetic counseling
psychological, 51–54
Counseling sessions, 47
Cowden’s disease, 103
genetic testing for, 5
mode of inheritance for, 41
Cryptorchid testis, 226
CYP1A1, 104

D
Denys-Drash syndrome, 214
Desmoid tumors, 137–138, 149, 150
Diagnoses, verifying, importance of, 40
DNA analysis, 61
DNA mismatch repair genes, 173–174
Duodenal adenomas, 148–149

E
Embryos, genetic testing of, 73–74
Empathy, 53–54
Employee Retirement Security Act (ERISA), 87
Employment opportunities, 78
Endometrial carcinoma, 198

Equal Employment Opportunity Commission (EEOC), 88
Ethical issues in genetic testing, 61–80
Ethnic background, 39
Eugenics, 32

F
Fair treatment in genetic testing, 74–79
principle of, 62
Familial adenomatous polyposis (FAP), 15–17, 136–150
attenuated, 139–140
clinical variants, 139–140
clinicopathologic features, 136
diagnosis and evaluation, 140–141
extracolonic manifestations, 136, 137
management of, 141–143
surgical therapy, 144–148
Familial medullary thyroid cancer, 245–246
Familial polyposis, genetic testing for, 5
Family history (FH), 36
assessing, 3–4
of cancer information collecting, 2–3
elements of, 2
of site-specific cancer, 1
Family History of Disease Assessment form, 3
Fetuses, genetic testing of, 73–74
Fundic gland polyp, 137

G
Gail model, 7, 42, 45, 94–95
Gardner’s syndrome, 139, 140
Gastroduodenal polyps, 137
Gastrointestinal polyps, 150–151
Genetic aspects of urological malignancies, 205–230
Genetic counseling, 30
case presentations, 55–58
current philosophy in, 31–33
definition, 33
for inherited cancer syndromes, 30–58
process of, 31
Genetic counselors, 33–34

Genetic information insurers and, 84–85
legislative attempts to regulate, 86–88
in workplace, 86
Genetic risk of cancer, assessing, 1–23
for colorectal cancer, assessing, 15–18
for melanoma, assessing, 19–21
Genetic test results, 50
Genetic testing, 1, 48–49
autonomy in, 66–74
ethical issues in, 61–80
fair treatment in, 74–79
of fetuses or embryos, 73–74
for inherited cancer syndromes, 5
patient welfare and, 62–66
Glutathione S-transferases, 104
Gonadoblastoma, 191
Gorlin’s syndrome, 191
Growth factors/receptors, 111

H
Health insurance, 75–77
Health Insurance Portability and Accountability Act (HIPPA), 109
Hereditary cancer syndromes.  See Inherited cancer syndromes
Hereditary nonpolyposis colorectal cancer (HNPCC), 15, 18–19, 166–180
case presentations, 56–58
clinical features, 168–170
diagnosis of, 176–177
diagnostic criteria, 170–176
features of, 167
genetic testing for, 5
history, 166–168
management of, 178–180
models, 45–46
screening for, 177–178
Hereditary papillary renal cell (HPRC) carcinoma, 219–220
Hereditary risk for breast cancer, identifying, 104–109
HER2/neu overexpression, 116–117
HNPCC. See Hereditary nonpolyposis colorectal cancer

Human Genome Project (HGP), 83–84

I

Ileal pouch anal anastomosis (IPAA), 146–147
Ileorectal anastomosis (IRA), 145–146
Informed consent, 49–50
Inherited cancer syndromes genetic counseling for, 30–58 genetic testing for, 5
Insurers, genetic information and, 84–85
International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC), 170

Intestinal polyps, 152 management of, 143–148 Ionizing radiation, 94

J

Justice, principle of. See Fair treatment
Juvenile polyposis syndromes, 152–154

L

Legislative attempts to regulate genetic information, 86–88
Li-Fraumeni syndrome, 102, 103 genetic testing for, 5
Lynch syndrome. See also Hereditary nonpolyposis colorectal cancer
Lynch syndromes I and II, 224

M

Malignant melanoma, genetic testing for, 5
Mastectomy, bilateral prophylactic, 64
Matrix metalloproteases (MMPs), 118
Medical history, complete, 36
Medical information collecting, 34–35 confidentiality of, 69–70 Medical record, privacy and, 88–89

Medullary thyroid cancer, familial, 245–246 Melanoma, genetic risk for, assessing, 19–21 Melanoma, genetic testing for, 5
MEN. See also Multiple endocrine neoplasia MEN1, 242–244 genetics, 243–244 MEN2, 244–245 genetics, 244–245 MEN2A, 241, 244 genetic testing for, 5 screening and surgical intervention for, 245 MEN2B, 241, 244 genetic testing for, 5 mode of inheritance for, 41 Menin, 243–244

Microsatellite instability, 172–173 Minimal deviation adenocarcinoma (MDC) of cervix, 198–199 Modifier genes, 104

Molecular-based therapy, 116–117
Muir-Torre syndrome, 103, 224 genetic testing for, 5 mode of inheritance for, 41
Multiple endocrine neoplasia (MEN), 21. See also MEN entries
genetics of, 241–246 Myriad Genetics Laboratories, 7

N

National Cancer Institute, 7
Nephroblastoma. See Wilms’ tumor
Neurofibromatosis 1 genetic testing for, 5 mode of inheritance for, 41
Neurofibromatosis 2, genetic testing for, 5 Nonsteroidal anti-inflammatory drugs (NSAIDs), 194–195

O


P

Prostate cancer *(continued)*
screening for, 212
specific alleles, 210–211
Psychological counseling,
51–54

R
Renal cell carcinoma, 216–222
candidate alleles, 219–221
clinical implications, 221–222
incidence, 216–217
specific alleles, 217–219
Renal pelvis cancer
clinical implications, 225
epidemiology, 222–224
incidence, 222
potential alleles, 224–225
specific alleles, 225
Retinoblastoma, genetic testing
for, 5
Retinoid derivatives, 196
Risk assessment, 41–46
Risk management discussion,
51
Risk of ovarian cancer
algorithm (ROCA), 192

S
Screening exams, 57n
Sporadic cancer, 4
Surrogate endpoint biomarkers
(SEBs), 109, 114–115
Survivor guilt, 53

T
Tamoxifen, 64, 91, 97–98
Testicular cancer, 225–230
clinical implications,
229–230
familial clustering, 226–227
incidence, 225–226
inheritance patterns, 227–228
potential alleles, 228–229
Testis, cryptorchid, 226
Thyroid cancer, medullary,
familial, 245–246
Thyroid malignancy, 138–139
Transitional cell carcinoma-
associated syndromes, 224
Turcot syndrome, 140
genetic testing for, 5
mode of inheritance for, 41

U
Ureteral cancer
clinical implications, 225
epidemiology, 222–224
incidence, 222
potential alleles, 224–225
specific alleles, 225
Urological malignancies,
genetic aspects of, 205–230

V
Verifying diagnoses,
importance of, 40
Von Hippel-Lindau disease,
217, 218–219
genetic testing for, 5

W
WAGR syndrome, 213
Web site www.genetests@
genetests.org, 4
Werner’s syndrome, 242
Wilms’ tumor, 212–216
associated abnormalities,
213–214
clinical implications, 216
genetic testing for, 5
incidence, 212
patterns of inheritance,
212–213
potential alleles, 215–216
specific alleles, 214–215
Workplace, genetic information
in, 86

X
X-linked transmission, 207–208